NTLA – intellia therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Intellia (NTLA) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Intellia Therapeutics GAAP EPS of -$0.83 beats by $0.12, revenue of $23.02M beats by $10.85M [Seeking Alpha]
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Form S-8 Intellia Therapeutics,
Form 10-K Intellia Therapeutics, For: Dec 31
Form 8-K Intellia Therapeutics, For: Feb 26
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: GOLDMAN SACHS GROUP INC
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: Contrarius Investment Management Ltd
Top News Decliners
3/13 Form 8-K Intellia Therapeutics, For: Mar 12 -17.6%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.